https://openbell.ai/ 2026-11-09T18:43:17.686Z hourly 1.0 https://openbell.ai/support 2026-11-09T18:43:17.686Z monthly 0.7 https://openbell.ai/privacy 2026-11-09T18:43:17.686Z monthly 0.5 https://openbell.ai/terms 2026-11-09T18:43:17.686Z monthly 0.5 https://openbell.ai/feed.json 2026-11-09T18:43:17.686Z hourly 0.8 https://openbell.ai/news/JAZZ:1794247300000 2026-11-09T18:01:40.000Z daily 0.9 https://cdn.brandfetch.io/JAZZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jazz Pharmaceuticals Raises 2026 Revenue Outlook Jazz Pharmaceuticals raised its 2026 revenue outlook to $4.775 billion–$4.85 billion. Third-quarter sales grew 12% year over year for Xywav and 32% for Zepzelca, partly offset by declines in Epidiolex and Xyrem sales. The company maintained gross-margin guidance of 89%–90% and expects a GAAP tax rate of 20%–30%. https://openbell.ai/news/AIR:1794247300000 2026-11-09T18:01:40.000Z daily 0.9 https://cdn.brandfetch.io/AIR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Airbus and Thales Alenia Space Awarded €1.5 Billion French Military Satellite Contract Airbus and Thales Alenia Space won a French military contract worth more than €1.5 billion ($1.67 billion) to build two observation satellites for the IRIS project. The work covers satellite design, manufacturing and testing, ground systems, and in-orbit operations and maintenance, with Airbus leading the platforms and ground segment and both companies contributing to the payloads. The project is expected to continue through the end of the next decade and is intended to support France’s strategic autonomy. https://openbell.ai/news/CMPS:1794245512000 2026-11-09T17:31:52.000Z daily 0.9 https://cdn.brandfetch.io/CMPS/w/400/h/400?c=1idopYfmtR7ZKg8QMud COMPASS Pathways Completes NDA Submission for COMP360 Psilocybin COMPASS Pathways completed its New Drug Application submission to the FDA for COMP360, its proprietary synthetic psilocybin therapy for treatment-resistant depression. The company is targeting a commercial launch in the first half of 2027, subject to regulatory approval and DEA rescheduling. https://openbell.ai/news/DOLE:1794245495000 2026-11-09T17:31:35.000Z daily 0.9 https://cdn.brandfetch.io/DOLE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Dole plc Reports Q3 2026 Earnings and Lowers Full-Year Profit Outlook Dole plc reported Q3 2026 revenue of $2.37 billion, in line with expectations, and adjusted diluted EPS of $0.16, below the $0.34 analyst consensus. Net income was $48.3 million and included a $48.6 million gain from selling its Ecuador port operations. The company lowered its full-year adjusted EBITDA guidance to a midpoint of $385 million from approximately $400 million, citing higher fuel and shipping costs and adverse weather. Fresh Fruit revenue fell 8% amid lower banana and pineapple volumes, while diversified fresh produce grew, supported by acquisitions. https://openbell.ai/news/AMCR:1794243708000 2026-11-09T17:01:48.000Z daily 0.9 https://cdn.brandfetch.io/AMCR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Amcor Reports Quarterly Financial Results and Updates Guidance Amcor reported September 2026-quarter sales of $6.13 billion, up 7%, while adjusted EPS fell to $0.95. Citing higher energy and distribution costs, the company lowered its semi-annual EPS forecast to $1.70–$1.80. Amcor recorded $60 million in quarterly synergies and reaffirmed targets of $130 million during the transition period and $650 million over three years; growth synergies added $170 million in annual sales. https://openbell.ai/news/CRSP:1794243703000 2026-11-09T17:01:43.000Z daily 0.9 https://cdn.brandfetch.io/CRSP/w/400/h/400?c=1idopYfmtR7ZKg8QMud CRISPR Therapeutics Presents Positive Phase 1b Clinical Data for CTX310 CRISPR Therapeutics reported Phase 1b results for CTX310, an investigational in vivo CRISPR/Cas9 therapy targeting ANGPTL3 in severe hypertriglyceridemia. At Day 30, a single treatment produced mean reductions from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides among participants whose median baseline triglyceride level exceeded 1,000 mg/dL. The data were presented at the 2026 American Heart Association Scientific Sessions, and the FDA has granted CTX310 RMAT designations for severe hypertriglyceridemia and elevated LDL-C. https://openbell.ai/news/OS:1794241959000 2026-11-09T16:32:39.000Z daily 0.9 https://cdn.brandfetch.io/OS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Officina Stellare Reports Strong Financial Growth and New Financing Officina Stellare reported sharp year-over-year growth in its order backlog and production value, alongside expanded margins and strong cash generation. It secured €75 million in financing to support growth, innovation, and recent M&A aimed at strengthening its technological capabilities in the aerospace and opto-mechanical sectors. The report did not provide specific growth rates, profit or revenue figures, or a stock-price impact. https://openbell.ai/news/CNCK:1794241943000 2026-11-09T16:32:23.000Z daily 0.9 https://cdn.brandfetch.io/CNCK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Coincheck Group Reports Financial Results for Second Quarter of Fiscal Year Ending March 31, 2027 Coincheck Group reported a 43% year-over-year revenue decline in the second quarter of fiscal 2027, citing weaker trading volumes, and swung to a net loss that included a ¥2.962 billion impairment related to its Aplo subsidiary. The company plans to wind down Aplo’s French brokerage operations and transfer its technology to 3iQ, targeting an SMA product launch in the first half of 2027. https://openbell.ai/news/ERAG:1794241929000 2026-11-09T16:32:09.000Z daily 0.9 https://cdn.brandfetch.io/ERAG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ernst Russ AG Raises Full-Year 2026 Forecast Ernst Russ AG raised its 2026 revenue forecast to EUR 159 million–EUR 164 million from EUR 150 million–EUR 160 million, and its EBIT outlook to EUR 63 million–EUR 70 million from EUR 55 million–EUR 65 million. The revision reflects a stronger US dollar, with the company now assuming an average rate of 1.12 USD/EUR for the rest of the year, versus 1.18 previously. The outlook also factors in fleet utilization of about 97% and existing charter agreements. https://openbell.ai/news/CFEB:1794241921000 2026-11-09T16:32:01.000Z daily 0.9 https://cdn.brandfetch.io/CFEB/w/400/h/400?c=1idopYfmtR7ZKg8QMud CFE Reports Strong Operational Performance and Profit Growth Compagnie d’Entreprises CFE reported year-over-year growth of 51% in operating income and 72% in net profit, despite revenue declining 2.6%. Strong performance in its Construction & Renovation and VMA segments offset challenges in Real Estate Development and MOBIX. The company also reported a robust order book and a strong net cash position.